Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5

Author: Benzinga Newsdesk | August 09, 2022 07:27am
RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.

Posted In: GBT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist